^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    emfizatamab (GNC-038)

    i
    Other names: GNC-038, GNC038, GNC 038
    Associations

    News

    Trials
    Company:
    Biokin Pharma
    Drug class:
    PD-L1 inhibitor, CD3 agonist, CD19 inhibitor, CD137 agonist
    Related drugs:
    Associations

    News

    Trials
    2ms
    A Study of GNC-038 Injection in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma (clinicaltrials.gov)
    P1/2, N=40, Recruiting, Sichuan Baili Pharmaceutical Co., Ltd. | Trial completion date: Dec 2025 --> Dec 2027 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    emfizatamab (GNC-038)
    2ms
    A Study of GNC-038, a Tetra-specific Antibody, in Participants With R/R Diffuse Large B-cell Lymphoma (DLBCL) (clinicaltrials.gov)
    P1/2, N=12, Active, not recruiting, Sichuan Baili Pharmaceutical Co., Ltd. | Recruiting --> Active, not recruiting | N=20 --> 12
    Enrollment closed • Enrollment change
    |
    emfizatamab (GNC-038)
    2ms
    Phase I Clinical Study of GNC-038 in Patients With Non-Hodgkin's Lymphoma or Acute Lymphoblastic Leukemia (clinicaltrials.gov)
    P1, N=47, Active, not recruiting, Sichuan Baili Pharmaceutical Co., Ltd. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    emfizatamab (GNC-038)
    2ms
    A Study of GNC-038, a Tetra-specific Antibody, in Patients With Central Nervous System Lymphoma (PCNSL) and Relapsed or Refractory Secondary Central Nervous System Lymphoma (SCNSL) (clinicaltrials.gov)
    P1/2, N=7, Active, not recruiting, Sichuan Baili Pharmaceutical Co., Ltd. | Recruiting --> Active, not recruiting | N=33 --> 7
    Enrollment closed • Enrollment change
    |
    emfizatamab (GNC-038)
    2ms
    A Study of GNC-038 Injection in Patients With Relapsed or Refractory NK/ T-cell Lymphoma, AITL, and Other NHL (clinicaltrials.gov)
    P1/2, N=4, Active, not recruiting, Sichuan Baili Pharmaceutical Co., Ltd. | Recruiting --> Active, not recruiting | N=40 --> 4
    Enrollment closed • Enrollment change
    |
    emfizatamab (GNC-038)
    3ms
    A Study of GNC-038, a Tetra-specific Antibody, in Participants With R/R Diffuse Large B-cell Lymphoma (DLBCL) (clinicaltrials.gov)
    P1/2, N=20, Recruiting, Sichuan Baili Pharmaceutical Co., Ltd. | Trial primary completion date: Jun 2025 --> Dec 2025
    Trial primary completion date
    |
    emfizatamab (GNC-038)
    3ms
    A Study of GNC-038 Injection in Patients With Relapsed or Refractory NK/ T-cell Lymphoma, AITL, and Other NHL (clinicaltrials.gov)
    P1/2, N=40, Recruiting, Sichuan Baili Pharmaceutical Co., Ltd. | Trial primary completion date: Jun 2025 --> Dec 2025
    Trial primary completion date
    |
    emfizatamab (GNC-038)
    3ms
    Phase I Clinical Study of GNC-038 in Patients With Non-Hodgkin's Lymphoma or Acute Lymphoblastic Leukemia (clinicaltrials.gov)
    P1, N=41, Recruiting, Sichuan Baili Pharmaceutical Co., Ltd. | Trial primary completion date: Jun 2025 --> Dec 2025
    Trial primary completion date
    |
    emfizatamab (GNC-038)
    4ms
    A Study of GNC-038 Injection in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma (clinicaltrials.gov)
    P1/2, N=40, Recruiting, Sichuan Baili Pharmaceutical Co., Ltd. | Trial primary completion date: Jun 2025 --> Dec 2025
    Trial primary completion date
    |
    emfizatamab (GNC-038)
    5ms
    A Study of GNC-038 Tetra-specific Antibody Injection in Patients With Systemic Lupus Erythematosus (clinicaltrials.gov)
    P1, N=54, Recruiting, Sichuan Baili Pharmaceutical Co., Ltd. | Not yet recruiting --> Recruiting | Initiation date: Mar 2025 --> Jun 2025
    Enrollment open • Trial initiation date
    |
    emfizatamab (GNC-038)
    6ms
    A Study of GNC-038, a Tetra-specific Antibody, in Patients With Central Nervous System Lymphoma (PCNSL) and Relapsed or Refractory Secondary Central Nervous System Lymphoma (SCNSL) (clinicaltrials.gov)
    P1/2, N=33, Recruiting, Sichuan Baili Pharmaceutical Co., Ltd. | Trial completion date: May 2025 --> Dec 2025 | Trial primary completion date: May 2025 --> Dec 2025
    Trial completion date • Trial primary completion date
    |
    emfizatamab (GNC-038)
    8ms
    A Study of GNC-038 Tetra-specific Antibody Injection in Patients With Rheumatoid Arthritis (clinicaltrials.gov)
    P1, N=54, Recruiting, Sichuan Baili Pharmaceutical Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    emfizatamab (GNC-038)